Consensus Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 09/07/2025 am IST			5-day change	1st Jan Change
19.03 ^USD	+9.87%		+7.45%	-84.35%

01/07	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell Midcap Value Index	CI
01/07	Sarepta Therapeutics, Inc.(NasdaqGS:SRPT) added to Russell 3000 Value Index	CI

Evolution of the Average Target: Sarepta Therapeutics, Inc.

Evolution of the Target Price: Sarepta Therapeutics, Inc.

Changes in Analyst Recommendations: Sarepta Therapeutics, Inc.

bf.IdsIMy0jWwB2T3MzG381_Rb8qUm2ypjQkTZiCNaYRwM.SLVKQXsREnkRECEDTC8GpVe27X7Opuyk5XQPRJvLdWVz9lh7eVModQc6Kg~0b2b99782cc12625c617a7d13ea0b99c

Analysts' recommendations: Sarepta Therapeutics, Inc.

William Blair Downgrades Sarepta Therapeutics to Market Perform From Outperform	20/06	MT
Goldman Sachs Downgrades Sarepta Therapeutics to Neutral From Buy, Adjusts Price Target to $29 From $100	18/06	MT
TD Cowen Downgrades Sarepta Therapeutics to Hold From Buy, Cuts Price Target to $24 From $62	18/06	MT
Analysts recommendations: Sarepta Therapeutics, Broadcom, Enphase Energy, Lam Research…	18/06
Deutsche Bank Halves Price Target on Sarepta Therapeutics to $25 From $50, Keeps Hold Rating	17/06	MT
Wolfe Research Initiates Coverage on Sarepta Therapeutics With Peer Perform Rating	17/06	MT
Analyst recommendations: Cisco, Roku, Coreweave, Robinhood…	17/06
Morgan Stanley Downgrades Sarepta Therapeutics to Equalweight From Overweight, $40 Price Target; Shares Fall	17/06	MT
Jefferies Cuts Sarepta Therapeutics' Price Target to $54 From $125, Buy Rating Maintained	16/06	MT
Cantor Fitzgerald Downgrades Sarepta Therapeutics to Neutral From Overweight, $20 Price Target; Shares Plunge	16/06	MT
Needham Adjusts Price Target on Sarepta Therapeutics to $50 From $125, Maintains Buy Rating	16/06	MT
RBC Adjusts Price Target on Sarepta Therapeutics to $25 From $58, Maintains Sector Perform Rating	16/06	MT
HC Wainwright Downgrades Sarepta Therapeutics to Sell From Neutral, Adjusts PT to $10 From $40	16/06	MT
Piper Sandler Downgrades Sarepta Therapeutics to Neutral From Overweight, Adjusts PT to $36 From $70	16/06	MT
BMO Capital Downgrades Sarepta Therapeutics to Market Perform From Outperform, Adjusts PT to $70 From $120	16/06	MT
Analyst recommendations: Adobe, Spotify, Blackrock, On Semiconductors…	16/06
Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform From Sector Perform, $80 Price Target	06/06	MT
Analyst recommendations: Crowdstrike Holdings, Broadcom, Lululemon, Zscaler…	06/06
Analyst recommendations; Applovin, HP, Metlife, Micron, Pure Storage….	20/05
Analyst recommendations: Nvidia, On Holding, Duolingo, Target, UnitedHealth…	15/05
Analyst recommendations: Airbnb, AMD, Fortinet, Uber, Estee Lauder…	09/05
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating	08/05	MT
Analyst recommendations: Skechers, Doordash, Stellantis, The Trade Desk, Yeti Holdings…	07/05
BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating	17/04	MT
Wells Fargo Initiates Sarepta Therapeutics at Overweight With $115 Price Target	11/04	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus (Composite)	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Ecart obj. / dr
	SAREPTA THERAPEUTICS, INC.					+177.36%
	ULTRAGENYX PHARMACEUTICAL INC.					+127.48%
	Average					+152.42%
	Weighted average by Cap.					+143.09%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

19.03USD

Average target price

48.04USD

Spread / Average Target

+152.44%

High Price Target

110.00USD

Spread / Highest target

+478.03%

Low Price Target

10.00USD

Spread / Lowest Target

-47.45%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

William Blair & Co.
Goldman Sachs
TD Cowen
Deutsche Bank Securities
Wolfe Research
Morgan Stanley
Jefferies & Co.
Cantor Fitzgerald
Needham & Co.
RBC Capital Markets
HC Wainwright
Piper Sandler
BMO Capital
Scotiabank
UBS
BofA Securities
Wells Fargo Securities
Oppenheimer
Barclays
Baird
Mizuho Securities
Wedbush
JPMorgan Chase
Citigroup
Evercore ISI
Credit Suisse
Berenberg Bank
BTIG
SVB Securities LLC
Guggenheim